Status:
COMPLETED
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Lead Sponsor:
Yale University
Collaborating Sponsors:
American Heart Association
Conditions:
Myocardial Infarction
Eligibility:
All Genders
21-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Patients with heart attacks are treated with medicines to reduc...
Detailed Description
Anti-apoptotic effects of erythropoietin in experimental myocardial infarction (MI) and ischemia-reperfusion injury suggest potential for therapeutic benefit in patients with acute MI. Before the ther...
Eligibility Criteria
Inclusion
- Age 21-75 years
- Clinical evidence of acute myocardial infarction (MI) with total or sub-total occlusion on angiogram
- Status post percutaneous revascularization procedure for acute MI with TIMI 3 flow
- Ongoing clinically-indicated treatment with aspirin, thienopyridines
Exclusion
- Hemodynamic instability/shock or severe congestive heart failure
- Time from onset of chest pain to revascularization procedure \> 16 hours
- Use of intravenous thrombolytic agents for treatment of MI
- Known need for additional revascularization procedures
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00367991
Start Date
November 1 2006
End Date
March 1 2008
Last Update
January 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06510